Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: bevacizumab
DATE: 23/02/2024
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
